AVIR
Atea Pharmaceuticals Inc.
$4.19
+$0.04(+0.96%)
36
Overall
60
Value
20
Tech
28
Quality
Market Cap
$258.71M
Volume
211.62K
52W Range
$2.46 - $6.45
Target Price
$8.00
Company Overview
| Mkt Cap | $258.71M | Price | $4.19 |
| Volume | 211.62K | Change | +0.96% |
| P/E Ratio | -1.5 | Open | $4.13 |
| Revenue | -- | Prev Close | $4.15 |
| Net Income | $-168.4M | 52W Range | $2.46 - $6.45 |
| Div Yield | N/A | Target | $8.00 |
| Overall | 36 | Value | 60 |
| Quality | 28 | Technical | 20 |
No chart data available
About Atea Pharmaceuticals Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Sector: Industrials
Industry: Pharmaceutical Preparation Manufacturing
Latest News
Atea Pharmaceuticals (AVIR) Receives a Hold from Morgan Stanley
TipRanks Auto-Generated Intelligence Newsdesk•2 days ago
Analysts Are Bullish on Top Healthcare Stocks: Agios Pharma (AGIO), Atea Pharmaceuticals (AVIR)
Brian Anderson•21 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AVIR | $4.19 | +1.0% | 211.62K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Atea Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW